Medicus Sciences Acquisition Corp.
| IPO Proceeds, $M | $92.00M |
|---|---|
| IPO Date | Feb 16, 2021 |
| CEO | Michael Castor, M.D. |
| Left Lead | Maxim |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Medical technology |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Feb 21, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Medicus Sciences Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 11 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jacob Gottlieb, M.D. | 49 | Executive Chairman |
| Michael Castor, M.D. | 49 | Chief Executive Officer & Director |
| Neil Puri | Chief Business Officer | |
| Judah Drillick | 44 | Chief Financial Officer |
| Kenneth Berkovitz, M.D., F.A.C.C. | 46 | Director |
| Christopher Kaster | 49 | Director |
| Ross Levine, M.D. | 48 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Maxim | BR | 8,000,000 | units |
| 8,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
2.50 | % |
Sign in to view more advisor data.
Filings
| Dec 23, 2020 | Initial S-1 |
| Jan 28, 2021 |
S-1/A Amendment #1
Sign In to view filing content. |
| Feb 3, 2021 |
S-1/A Amendment #2
Sign In to view filing content. |
| Feb 15, 2021 |
PR announcing pricing of $80mm IPO
Sign In to view filing content. |
| Feb 17, 2021 | 424B4 IPO Prospectus |
| Feb 19, 2021 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |
| Apr 1, 2021 |
8-K announcing separate trading of common stock and warrants
Sign In to view filing content. |
| Feb 8, 2022 |
8-K announcing proposed letter of intent with Anteris Technologies Ltd
Sign In to view filing content. |
| Feb 15, 2022 |
8-K announcing cessation of discussion with Anteris
Sign In to view filing content. |
| Mar 28, 2022 |
8-K announcing change in directors
Sign In to view filing content. |
| Feb 13, 2023 |
8-K announcing liquidation and redemption of public shares
Sign In to view filing content. |